Qiagen: 3rd-Qtr And 9 Mth Financial Results
- Revenues for third-quarter 1996 at Qiagen were up 50% from the like period of 1995 to $14.2 million. Net sales increased 51% in the USA and 48% outside the USA, due to ongoing market penetration of products. Net income for the quarter increased 112% to $1.5 million or $0.06 per share, up from $687,000 or $0.05 per share in 1995. Net sales for the first nine months were $39.2 million, up from $26.5 million in 1995. Net income was $3.5 million with earnings per share of $0.23, compared to a net income of $1.6 million or $0.12 per share in 1995.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze